Conference Detail Page

Metastatic Breast Cancer: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care

Contact Hours : 1.25
Start Date :  Dec 28 - 2020 End Date :  Dec 27 - 2021

Organized by :   i3 Health

Specialities :   Oncology, Obstetrics and Gynecology, OBGYN and Women's Health

Conference Summary

Metastatic Breast Cancer: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care is organized by i3 Health.

Release Date: Dec 28, 2020
Expiration Date: Dec 27, 2021.

Accreditation:
Nurses:
Nursing Continuing Professional Development

i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.25 contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.25 contact hours.

Statement of Need:
Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population (ACS, 2019). Although many women benefit from regular screening as well as earlier and improved treatment, approximately 6% present with metastatic disease, and up to 30% with no initial lymph node involvement eventually develop metastatic disease (Siegel et al, 2019; Mortensen et al, 2018). Women with MBC have a poorer prognosis than the overall population of breast cancer patients, and issues such as refractory or resistant disease, cumulative toxicities, adverse events, depression, and financial hardship are often encountered (Mortensen et al, 2018). Despite progress in understanding the pathogenesis of MBC and advances in therapy, the 5-year overall survival rate remains only 27% (Siegel et al, 2019).

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Identify prognostic markers that impact treatment selection and treatment goals to individual patients with metastatic breast cancer (MBC)
• Evaluate the efficacy and safety profiles of novel therapies for HER2-positive, HER2-negative, and triple-negative MBC
• Assess strategies to manage treatment-related adverse events, promote adherence to therapy, and ensure patient-centered MBC care

Faculty:
• Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN (Chairperson)
Nurse Practitioner
Memorial Sloan Kettering Cancer Center

Credit Info

  • Contact Hours : 1.25
Additional Info

Social Media Info :

Speaker (s)
1 Speakers
Target Audience

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with MBC.

Peers Info
Number of Health Care Professionals Registered: 0 Number
Contact Us

Toll free Number

1(800) 826-2059

Email

support@eMedEvents.com

Chat Assistant

Live Chat